Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical formulation for treating cardiovascular diseases

A cardiovascular and disease technology, applied in the field of drug formulations for disease treatment, can solve the problems of restricting clinical application, limited relief of sympathetic hypertonia, multiple side effects, etc., and achieve the effect of reducing the incidence of toxic and side effects, reducing dosage, and effective therapeutic effect

Inactive Publication Date: 2015-11-25
何功浩
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the traditional β1 receptor antagonists are still limited in alleviating the body's sympathetic hypertonicity in the treatment of clinically relevant diseases, and there are many side effects, which restrict its wider clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] The present invention will be further described below:

[0011] The present invention is composed of chondroitin sulfate, notopterygium, velvet antler, honeysuckle, scrophulariaceae, sugar octaacetate, orange red essence, Huoxiang essence, beta cyclodextrin, scallion, hawthorn, Corydalis, kudzu root, safflower, peach kernel, ginkgo leaf , Prunella vulgaris, pine needles, Sophora japonica, wild chrysanthemum, pig bile, dried white peony root, H2 receptor antagonist and β1 receptor antagonist.

[0012] Preferably, the chondroitin sulfate accounts for 3%, the notopterygium accounts for 8%, the pilose antler accounts for 5%, the honeysuckle accounts for 8%, the Scrophulariaceae accounts for 5%, and the sugar octaacetate accounts for 3%. %, the orange essence accounts for 2%, the patchouli essence accounts for 5%, the beta-cyclodextrin accounts for 3.5%, the scallion accounts for 7.5%, the hawthorn accounts for 10%, and the corydalis accounts for 3% , the kudzu root account...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical formulation for treating cardiovascular diseases. The pharmaceutical formulation comprises chondroitin sulfate, notopterygium root, cornua cervi pantotrichum, honeysuckle, radix scrophulariae, sucrose octaacetate, orange essence, agastache rugosus essence, betacyclodextrin, longstamen onion bulb, hawthorn, corydalis tuber, radix pueraiae, red flower, peach kernel, ginkgo leaf, selfheal, pine needle, sophora japonica, chrysanthemum indicum, pig's bile, dried white peony root, H2 receptor antagonist and beta 1 receptor antagonist. The pharmaceutical formulation has the advantages that the beta 1 receptor antagonist and the H2 receptor antagonist are combined with the traditional Chinese medicine to prepare new compound drug preparation, the preparation has a sympathetic activity resisting effect in vivo, and the effect directions are consistent; due to the fact that effect targets of the beta 1 receptor antagonist and the H2 receptor antagonist are different, effective synergy is achieved, that is to say, the use amount of the beta 1 receptor antagonist and the H2 receptor antagonist can be reduced, toxic and side effect occurrence rate can be lowered, curative effect can be brought into play through various channels, effective therapeutic effects on the cardiovascular diseases including coronary heart diseases, arrhythmia, hypertension and congestive heart failure can be achieved, and the pharmaceutical formulation is worthy of popularization and application.

Description

technical field [0001] The invention relates to a medicine formula for treating diseases, in particular to a medicine formula for treating cardiovascular diseases. Background technique [0002] Sympathetic hypertonicity is an important factor in the pathogenesis and malignant progression of a series of cardiovascular diseases such as coronary heart disease, arrhythmia, hypertension and congestive heart failure, and adrenergic antisympathetic drugs (β1 receptor antagonists) Its price is low, and it has been an important traditional first-line drug for the treatment of the above-mentioned cardiovascular diseases. However, the traditional β1 receptor antagonists are still limited in alleviating the body's sympathetic hypertonicity in the treatment of clinically relevant diseases, and there are many side effects, which restrict their wider clinical application. Contents of the invention [0003] The purpose of the present invention is to provide a drug formulation for treatin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K36/8962A61P9/00A61K35/413A61K35/32A61K31/737A61K31/165A61K31/426A61K31/138A61K31/4164
Inventor 何功浩徐贵丽贺娟蔡文科董自西
Owner 何功浩
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com